A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
A Phase I/II Study of GRN163L in Combination With Paclitaxel and Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Harvey, Illinois, United States, 60426
- Ingalls Memorial Hospital
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of the breast with measurable locally recurrent or metastatic disease
- May have had one prior non-taxane chemotherapy regimen for metastatic disease
- If HER2 positive, must have had prior treatment with trastuzumab (Herceptin®)
- If previously treated with an anthracycline, anthracenedione, or trastuzumab must be tested by MUGA scan or echocardiogram and have LVEF ≥ 50%
- Must have recovered from most recent radiation treatment or surgical procedure
- ECOG performance status of 0 or 1
- Life expectancy ≥ 3 months
Exclusion Criteria:
- Locally recurrent disease amenable to resection with curative intent
- Prior adjuvant or neoadjuvant taxane chemotherapy within 12 months prior to first study drug administration
- Investigational therapy within 4 weeks prior to first study drug administration
- Prior hormonal therapy within 2 weeks prior to first study drug administration
- Prior radiotherapy within 2 weeks prior to first study drug administration
- Cytotoxic chemotherapy within 2 weeks prior to first study drug administration
- Therapeutic anticoagulation or regular use of anti-platelet therapy within 2 weeks prior to first study drug administration NOTE: Low-dose anticoagulant therapy to maintain patency of a vascular access device is allowed.
- Prolongation of PT or INR, aPTT > ULN, or fibrinogen < LLN
- Active or chronically current bleeding (eg, active peptic ulcer)
- Clinically significant cardiovascular or cerebrovascular disease including
Any history of:
- Cerebrovascular disease including TIA, stroke or subarachnoid hemorrhage
- Ischemic bowel
Within the last 12 months:
- MI
- Unstable angina
- NYHA grade II or greater CHF
- Grade 2 or greater peripheral vascular disease
Active at study entry:
- Uncontrolled hypertension defined as SBP > 160 or DBP > 90
- Uncontrolled or clinically significant arrhythmia
- Clinically relevant active infection
- Nonhealing wound or fracture
- Serious co-morbid medical conditions, including cirrhosis and chronic obstructive or chronic restrictive pulmonary disease
- Active autoimmune disease requiring immunosuppressive therapy
- Known positive serology for HIV
- Prior malignancy (within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, or in situ prostate cancer, or other cancer for which the patient has been disease-free for at least 3 years
- Any other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality, or difficult complying with protocol requirements that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
3+3 cohort dose escalation
|
25% dose escalation infused over 2 hours weekly
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety, MTD, efficacy
Time Frame: First 4 weeks
|
First 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PK and efficacy
Time Frame: Baseline to end of treatment
|
Baseline to end of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kathy Miller, MD, Indiana University Melvin and Bren Simon Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GRN163L CP14A010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.